Intracranial Angioplasty and Stenting before and after SAMMPRIS: From simple to complex strategy - the Chinese experience

Intracranial atherosclerotic disease (ICAD) accounts for 33% to 50% of all ischemic strokes in the Asian population [1] and represents an important public health issue in China. The results of the SAMMPRIS trial alarmed most experienced interventionalists in China for two reasons. Firstly, the high...

Full description

Bibliographic Details
Main Author: Zhongrong eMiao
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-07-01
Series:Frontiers in Neurology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fneur.2014.00129/full
id doaj-672273f819d143d4b9f40115bad2221f
record_format Article
spelling doaj-672273f819d143d4b9f40115bad2221f2020-11-25T02:41:25ZengFrontiers Media S.A.Frontiers in Neurology1664-22952014-07-01510.3389/fneur.2014.0012989195Intracranial Angioplasty and Stenting before and after SAMMPRIS: From simple to complex strategy - the Chinese experienceZhongrong eMiao0Director of Interventional Neuroradiology, Beijing Tiantan hospital, Beijing Tiantan stroke center,Capital Medical University, Beijing, China.Intracranial atherosclerotic disease (ICAD) accounts for 33% to 50% of all ischemic strokes in the Asian population [1] and represents an important public health issue in China. The results of the SAMMPRIS trial alarmed most experienced interventionalists in China for two reasons. Firstly, the high complication rate in the stenting arm (20% the first year) was higher than expected. Secondly, the recurrent stroke rate in the aggressive medical treatment (AMT) arm at 12.2% during the first year was unacceptably high, not to mention the fact that such tight vascular risk factor control is difficult to achieve for many patients from real life clinical experience, at least in China. The experience of treating ICAD in China, gained over the last two decades, is very rich and promising. We intend to highlight these past experiences and address future trials and trends in China. We will also address our criticism of the SAMMPRIS trial design in order to better design a future trial.http://journal.frontiersin.org/Journal/10.3389/fneur.2014.00129/fullAngioplasty, Balloonischemic strokeintracranial atherosclerotic diseaseStentingmedical therapy
collection DOAJ
language English
format Article
sources DOAJ
author Zhongrong eMiao
spellingShingle Zhongrong eMiao
Intracranial Angioplasty and Stenting before and after SAMMPRIS: From simple to complex strategy - the Chinese experience
Frontiers in Neurology
Angioplasty, Balloon
ischemic stroke
intracranial atherosclerotic disease
Stenting
medical therapy
author_facet Zhongrong eMiao
author_sort Zhongrong eMiao
title Intracranial Angioplasty and Stenting before and after SAMMPRIS: From simple to complex strategy - the Chinese experience
title_short Intracranial Angioplasty and Stenting before and after SAMMPRIS: From simple to complex strategy - the Chinese experience
title_full Intracranial Angioplasty and Stenting before and after SAMMPRIS: From simple to complex strategy - the Chinese experience
title_fullStr Intracranial Angioplasty and Stenting before and after SAMMPRIS: From simple to complex strategy - the Chinese experience
title_full_unstemmed Intracranial Angioplasty and Stenting before and after SAMMPRIS: From simple to complex strategy - the Chinese experience
title_sort intracranial angioplasty and stenting before and after sammpris: from simple to complex strategy - the chinese experience
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2014-07-01
description Intracranial atherosclerotic disease (ICAD) accounts for 33% to 50% of all ischemic strokes in the Asian population [1] and represents an important public health issue in China. The results of the SAMMPRIS trial alarmed most experienced interventionalists in China for two reasons. Firstly, the high complication rate in the stenting arm (20% the first year) was higher than expected. Secondly, the recurrent stroke rate in the aggressive medical treatment (AMT) arm at 12.2% during the first year was unacceptably high, not to mention the fact that such tight vascular risk factor control is difficult to achieve for many patients from real life clinical experience, at least in China. The experience of treating ICAD in China, gained over the last two decades, is very rich and promising. We intend to highlight these past experiences and address future trials and trends in China. We will also address our criticism of the SAMMPRIS trial design in order to better design a future trial.
topic Angioplasty, Balloon
ischemic stroke
intracranial atherosclerotic disease
Stenting
medical therapy
url http://journal.frontiersin.org/Journal/10.3389/fneur.2014.00129/full
work_keys_str_mv AT zhongrongemiao intracranialangioplastyandstentingbeforeandaftersammprisfromsimpletocomplexstrategythechineseexperience
_version_ 1724778526445404160